|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4745 SEK | 0.00% |
|
-3.16% | -9.27% |
| Apr. 16 | Mendus AB Announces Board Changes | CI |
| Mar. 27 | Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML | CI |
Mendus AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was SEK 3.78 million compared to SEK 0.063 million a year ago. Net loss was SEK 41.17 million compared to SEK 43.28 million a year ago.
Basic loss per share from continuing operations was SEK 0.05 compared to SEK 0.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.27% | 43.59M | |
| +1.51% | 42.75B | |
| +48.66% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
MENDUS AB 
